Newsfeeds - Spark Newswire

1 minute read

Evercore ISI Group Upgrades BioCryst Pharmaceuticals to Outperform, Announces $16 Price Target

November 2, 9:30 AM

Evercore ISI Group analyst Liisa Bayko upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from In-Line to Outperform and announces $16 price target.

BCRX

1 minute read

RBC Capital Maintains Sector Perform on BioCryst Pharmaceuticals, Lowers Price Target to $13

By Benzinga Newsdesk

November 2, 8:22 AM

RBC Capital analyst Brian Abrahams maintains BioCryst Pharmaceuticals (NASDAQ:BCRX) with a Sector Perform and lowers the price target from $14 to $13.

BCRX

1 minute read

What’s Going On With BioCryst Pharmaceuticals Stock Today?

By Adam Eckert

November 1, 10:28 AM

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Tuesday after the company reported third-quarter financial results.

BCRX

1 minute read

Earnings

BioCryst Pharmaceuticals: Q3 Earnings Insights

By Benzinga Insights

November 1, 7:37 AM

BioCryst Pharmaceuticals (NASDAQ:BCRX) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

BCRX

1 minute read

BioCryst Secures FDA Orphan Drug Status For Rare Connective Tissue Disease Candidate

By Ragothaman Srinivasan

August 31, 8:03 AM

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for BioCryst’s (NASDAQ: BCRX) lead asset BCX9250 for the treatment of fibrodysplasia ossificans progressiva (FOP).

BCRX

1 minute read

BioCryst Pharmaceuticals Granted Orphan Drug Designation For The Treatment Of Fibrodysplasia Ossificans Progressiva

By Benzinga Newsdesk

August 29, 2:49 PM

https://www.scribd.com/document/589941834/BCRX-Orphan-Drug

BCRX

3 minute read

Recap Of Friday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

August 26, 7:52 PM

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor…

BCRX

1 minute read

BioCryst Exhibits Positive Data From Early-Stage Rare Kidney Disease Study

By Ragothaman Srinivasan

August 26, 8:50 AM

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced that its lead asset BCX9930 has demonstrated >99 percent suppression of the alternative pathway (AP), and that >98 percent suppression was maintained for 24 hours post-dosing, in patients with C3 glomerulopathy (C3G), a rare renal disease that is characterized by dysregulation of the AP of the complement system.

BCRX

2 minute read

Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

August 18, 6:19 PM

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA)…

AGLE

2 minute read

BioCryst Announces Approval Of ORLADEYO In Saudi Arabia

By Benzinga Newsdesk

August 18, 7:12 AM

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Saudi Food and Drug Authority (SFDA) has approved oral, once-daily ORLADEYO® (berotralstat) to prevent attacks of hereditary

BCRX